Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAWN NASDAQ:IBRX NASDAQ:KRYS NASDAQ:NUVL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsIBRXImmunityBio$7.89-0.4%$7.72$1.95▼$12.43$8.30B0.0213.48 million shs14.48 million shsKRYSKrystal Biotech$306.63+1.3%$275.34$123.03▼$319.48$8.92B0.5301,610 shs144,305 shsNUVLNuvalent$107.38+2.3%$102.56$70.25▼$113.01$8.29B1.15469,960 shs631,644 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%0.00%0.00%+102.16%+241.75%IBRXImmunityBio-0.38%-1.99%+8.23%-17.38%+211.86%KRYSKrystal Biotech+1.31%+1.52%+12.42%+10.95%+142.49%NUVLNuvalent+2.32%+4.95%+3.21%+3.32%+48.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAWNDay One Biopharmaceuticals$21.53$19.41$5.64▼$21.53$2.22B-1.741.52 million shs2.99 million shsIBRXImmunityBio$7.89-0.4%$7.72$1.95▼$12.43$8.30B0.0213.48 million shs14.48 million shsKRYSKrystal Biotech$306.63+1.3%$275.34$123.03▼$319.48$8.92B0.5301,610 shs144,305 shsNUVLNuvalent$107.38+2.3%$102.56$70.25▼$113.01$8.29B1.15469,960 shs631,644 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAWNDay One Biopharmaceuticals0.00%0.00%0.00%+102.16%+241.75%IBRXImmunityBio-0.38%-1.99%+8.23%-17.38%+211.86%KRYSKrystal Biotech+1.31%+1.52%+12.42%+10.95%+142.49%NUVLNuvalent+2.32%+4.95%+3.21%+3.32%+48.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAWNDay One Biopharmaceuticals 2.00Hold$23.298.15% UpsideIBRXImmunityBio 2.71Moderate Buy$14.2079.97% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.115.70% UpsideNUVLNuvalent 2.94Moderate Buy$140.2930.65% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, KRYS, NUVL, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$189.005/21/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.005/21/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/20/2026IBRXImmunityBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/8/2026IBRXImmunityBio BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.005/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/5/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAWNDay One Biopharmaceuticals$158.18M14.06N/AN/A$4.30 per share5.01IBRXImmunityBio$113.29M72.94N/AN/A($0.83) per share-9.51KRYSKrystal Biotech$389.13M23.23$7.39 per share41.52$43.31 per share7.08NUVLNuvalentN/AN/AN/AN/A$14.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAWNDay One Biopharmaceuticals-$107.32M-$1.03N/A2,153.00N/A-67.85%-23.43%-20.69%N/AIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4840.9929.15N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)Latest DAWN, KRYS, NUVL, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAWNDay One BiopharmaceuticalsN/A8.027.91IBRXImmunityBioN/A6.676.66KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAWNDay One Biopharmaceuticals87.95%IBRXImmunityBio8.58%KRYSKrystal Biotech86.29%NUVLNuvalent97.26%Insider OwnershipCompanyInsider OwnershipDAWNDay One Biopharmaceuticals6.20%IBRXImmunityBio69.48%KRYSKrystal Biotech13.10%NUVLNuvalent5.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAWNDay One Biopharmaceuticals60103.33 million96.93 millionOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableDAWN, KRYS, NUVL, and IBRX HeadlinesRecent News About These CompaniesNuvalent granted FDA priority review for lung cancer therapyMay 27 at 2:08 PM | msn.comNuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLCMay 27 at 6:30 AM | prnewswire.comBernstein initiates coverage of Nuvalent (NUVL) with outperform recommendationMay 23, 2026 | msn.comNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual MeetingMay 21, 2026 | prnewswire.comGuggenheim Sticks to Their Buy Rating for Nuvalent (NUVL)May 15, 2026 | theglobeandmail.comState of New Jersey Common Pension Fund D Sells 15,228 Shares of Nuvalent, Inc. $NUVLMay 11, 2026 | marketbeat.comUBS Group AG Acquires 185,932 Shares of Nuvalent, Inc. $NUVLMay 8, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) Announces Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comNuvalent (NASDAQ:NUVL) CEO Sells $3,050,700.00 in StockMay 7, 2026 | insidertrades.comNuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | prnewswire.comComerica Bank Grows Holdings in Nuvalent, Inc. $NUVLMay 7, 2026 | marketbeat.comCanaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL)May 6, 2026 | theglobeandmail.comJames Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) StockMay 6, 2026 | marketbeat.comNuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 6, 2026 | marketbeat.comVanguard Group Inc. Purchases 639,264 Shares of Nuvalent, Inc. $NUVLMay 5, 2026 | marketbeat.comInsider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of StockMay 1, 2026 | marketbeat.comNuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLCMay 1, 2026 | finance.yahoo.comNuvalent: A Precision Oncology Platform With Two Near-Term Shots On GoalApril 30, 2026 | seekingalpha.comGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ PlatformApril 30, 2026 | businesswire.comPictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVLApril 30, 2026 | marketbeat.comNuvalent (NUVL) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Qualcomm Stock Doubles: New Era? Or Another False Start?By Sam Quirke | May 13, 2026DAWN, KRYS, NUVL, and IBRX Company DescriptionsDay One Biopharmaceuticals NASDAQ:DAWNDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.ImmunityBio NASDAQ:IBRX$7.89 -0.03 (-0.38%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$7.88 -0.01 (-0.09%) As of 05/27/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Krystal Biotech NASDAQ:KRYS$306.63 +3.95 (+1.31%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$307.00 +0.37 (+0.12%) As of 05/27/2026 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$107.38 +2.43 (+2.32%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$107.36 -0.02 (-0.02%) As of 05/27/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
